The latest announcement is out from Xlife Sciences Ltd. ( (CH:XLS) ).
Xlife Sciences AG has released its 2024 annual report, highlighting a year of strategic partnerships and technological advancements within its portfolio companies. Key collaborations were formed with the Abu Dhabi Health Authority and Thermo Fisher Scientific, among others, while significant technological progress was made in areas such as liver diagnostics and cancer therapy. The company plans a dual listing on the Swiss and London Stock Exchanges to enhance international visibility and investor access. Despite a decrease in revenue, Xlife Sciences reported an increase in earnings per share and total assets, reflecting its strategic focus on scaling and innovation.
More about Xlife Sciences Ltd.
Xlife Sciences is a Swiss company that functions as an incubator and accelerator, focusing on the development and commercialization of promising research projects from universities and research institutions in the life sciences sector. The company aims to address high unmet medical needs and improve quality of life by bridging the gap between research and healthcare markets. Xlife Sciences selects projects in technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to advance their development and participate in their value growth.
YTD Price Performance: 2.36%
Average Trading Volume: 5,193
Current Market Cap: CHF136.7M
See more data about XLS stock on TipRanks’ Stock Analysis page.